Newsroom | 470225 results

Sorted by: Latest

Product/Service
-

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one...
-

Megaport Expands Global Automated Infrastructure Platform Into Portugal

BRISBANE, Australia--(BUSINESS WIRE)--Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more tha...
-

Fortem Technologies and MBDA Expand Partnership to Build Autonomous Counter-Drone Protection into European and Allied Air Defenses

WARSAW, Poland & WASHINGTON--(BUSINESS WIRE)--Fortem Technologies, a leader in layered airspace security and defense, today announced an expanded strategic partnership with European complex weapon systems leader MBDA to integrate Fortem’s autonomous counter-drone systems into the air-defense architectures operated by MBDA’s defense and government customers across Europe and worldwide. The agreement builds on a technical collaboration established in 2024 that integrated Fortem’s DroneHunter® aut...
-

e.l.f. Cosmetics Launches its First Virtual Styling Experience on ZEPETO: “Express Your e.l.f.”

OAKLAND, Calif.--(BUSINESS WIRE)--e.l.f. Cosmetics, a brand from e.l.f. Beauty (NYSE: ELF), is bringing its bold beauty approach to ZEPETO, an immersive, avatar-based social metaverse platform. Now available on ZEPETO, e.l.f. launched “Express your e.l.f.” where players can discover the beauty trends shaping culture and turn them into complete virtual looks from head to toe. The collaboration extends e.l.f.’s commitment to meeting its community in unexpected places and making the best of beauty...
-

Faraday Future Announces This Week’s Investor Weekly Report from YT Jia Has Been Rescheduled to October 14; FFR and FFAI to Host Joint New Product Launch Event on October 14

LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF,” or the “Company”), a California-based global Embodied AI (“EAI”) ecosystem company, today announced that this week’s Investor Weekly Report from FF Founder and Global CEO YT Jia has been rescheduled to October 14. Additionally, FFR and FFAI will host a joint new product launch event on October 14, 2026, featuring four major launches focused on embodied AI robotics, Physical AI educatio...
-

Sygnia Unveils Security Operations Center Hubs and Expands AI-Powered Cybersecurity Capabilities To Challenge Threat Attack Rise

TEL AVIV, Israel & AUSTIN, Texas & SINGAPORE--(BUSINESS WIRE)--Sygnia, the world’s foremost incident response and cyber readiness team, today announced it is establishing new MDR Security Operations Center (SOC) hubs in Austin, Texas, and Singapore. Together with Sygnia’s existing MDR operations in Tel Aviv, the new hubs will support a three-region, follow-the-sun operating model designed to strengthen 24/7 monitoring coverage, improve operational scalability, and enhance the customer experienc...
-

Publix Charities Donates $500,000 to Support Hurricane Isaias Relief Efforts

LAKELAND, Fla.--(BUSINESS WIRE)--Publix Super Markets Charities is making a $500,000 donation to United Way to help fund relief efforts for areas impacted by Hurricane Isaias. “Hurricane Isaias brought disruption and uncertainty to many of the communities we serve,” said Publix Charities Executive Director John Doran. “Supporting them during times of need is an important part of who we are, and we’re grateful for the opportunity to assist through an organization that helps those affected locall...
-

KAON Broadband Showcases Field-Proven prpl Deployments and Wi-Fi 8-Ready Platforms at prpl Summit 2026

VIENNA--(BUSINESS WIRE)--The prpl Foundation highlighted KAON Broadband’s participation in the prpl Summit 2026 as an Innovation Partner for Technical Day and a Technology Partner for Business Day. This partnership underscores KAON Broadband’s continued commitment to advancing open-source broadband platforms, backed by its extensive experience in commercial operator deployments and ongoing development of next-generation connectivity solutions. KAON Broadband has played an active role in bringin...
-

GoodVision AI to Showcase AI Inference Infrastructure at TechCrunch Disrupt 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)--GoodVision AI (“GoodVision”), a developer of next-generation AI compute infrastructure purpose-built for inference, today announced that it will exhibit at TechCrunch Disrupt 2026, taking place October 13–15, 2026, at Moscone West in San Francisco. The appearance follows the September 11 approval of GoodVision’s business combination with Calisa Acquisition Corp. (Nasdaq: ALIS), marking a new stage in the company’s development as it expands its AI inference...
-

Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the...